SHORT REPORT

Features of gastritis predisposing to gastric adenoma and early gastric cancer

A Meining, B Riedl, M Stolte

J Clin Pathol 2002;55:770-773

Background/Aims: *Helicobacter pylori* gastritis is a risk factor for the development of gastric cancer. The results of several studies indicate that gastric adenomas, which are considered premalignant lesions, may also be associated with *H pylori* gastritis. However, it is not clear whether there are different patterns of gastritis in these patients compared with patients with gastric cancer or patients with *H pylori* gastritis alone. Therefore, this study was designed to investigate the patterns of gastritis in these three groups of patients.

Methods: The histological features of gastric mucosa at a distance from the tumour were analysed prospectively in 118 patients with gastric adenoma (mean age, 71.8; female to male ratio, 6 : 4). In addition, for every patient with *H pylori* associated gastric adenoma an age and sex matched control patient with either *H pylori* associated early gastric cancer of the intestinal type or *H pylori* gastritis only was investigated.

Results: Only 60 patients (50.9%) with gastric adenoma were infected with *H pylori*. In the remaining patients, complete atrophic gastritis predominated. In those patients with adenoma and *H pylori* infection, the gastritis was similar to that seen in patients with early gastric cancer (median score, 2 for activity and degree of gastritis in the antrum and corpus); intestinal metaplasia was common to both groups. These two groups differed significantly from patients with *H pylori* gastritis only (median grade and activity of gastritis, 1 in antrum and corpus), in whom intestinal metaplasia was rare.

Conclusions: It appears that gastric adenomas and gastric intestinal cancer arise by analogous mechanisms. However, owing to severe atrophic gastritis and a lower incidence of *H pylori*, adenomas do not appear to be definite precursor lesions for gastric cancer.

It is known that infection with *Helicobacter pylori* always causes chronic active gastritis. Infection with the bacterium provokes invasion of the mucosa by lymphocytes/plasma cells (a marker for the grade of gastritis), and neutrophils (a marker for the activity of gastritis). In addition to these diffuse parameters, multifocal features such as intestinal metaplasia, atrophy, and lymphoid follicles may also be found in association with *H pylori* infection.¹

For gastric cancer of the intestinal type, Correa suggested a human model of carcinogenesis. He postulated that hyperproliferation caused by *H pylori* gastritis is the starting point of a sequence leading to gastric cancer.² This hyperproliferation may then initiate DNA alterations. The mutation of several antigens, such as Lewis a and carcinoembryonic antigen, suppressor genes, such as p53, or oncogenes, such as c-myc, APC/ β catenin, or ras, might be associated with the evolution from normal gastric mucosa to carcinoma.^{2,3} These changes are represented histopathologically by superficial gastritis leading to

Figure 1 Location of gastric adenomas (n = 118).

multifocal atrophy, intestinal metaplasia and, finally, dysplasia/cancer.² It has also been reported that cancers may develop via gastric adenomas⁴; hence—as for the carcinogenesis of colorectal carcinomas⁵—adenomas have been regarded as premalignant lesions.⁴

“Infection with *Helicobacter pylori* always causes chronic active gastritis”

However, data on gastric adenomas are still very sparse and, surprisingly, the incidence of gastric adenoma is much lower than that of gastric carcinoma.^{6,7} Hence, most gastric cancers do not develop via adenomas. In addition, in contrast to gastric cancer, little is known about the features of gastritis associated with gastric adenomas. This background prompted us to conduct a study, first to investigate the histopathological features of gastric adenomas—in particular the surrounding mucosa—and then to compare these findings with the patterns of gastritis in patients with early gastric cancer of the intestinal type and patients with gastritis alone.

PATIENTS AND METHODS

We analysed retrospectively all gastric adenomas investigated histopathologically at the pathological institute of Bayreuth between 1969 and 1996. For inclusion in the study, additional biopsies from the antrum and corpus mucosa at a distance from the tumour also had to be available; a total of 118 patients met these criteria. At the time of diagnosis, the patients' mean age was 71.8 years (SD, 11.37; range, 34–93). Forty seven patients (39.8%) were men and 71 (60.2%) were women. With the exception of one patient with an adenoma of the pyloric gland type (0.8%), all adenomas were of the intestinal type. Figure 1 shows the location of the adenomas in the stomach.

In addition, we included 60 patients with early gastric cancer of the intestinal type and histological evidence of *H pylori*,

Figure 2 Classification of gastritis in patients with gastric adenomas (%) (n = 118).

and a further 60 patients with *H. pylori* gastritis not associated with peptic ulcer or gastric malignancy. These patients had been matched by age (± 2 years) and sex to the 60 *H. pylori* infected patients with gastric adenoma. Data from the patients with *H. pylori* associated gastric cancer and from those with *H. pylori* gastritis alone were also collected retrospectively from the histopathological record forms at the pathological institute of Bayreuth. For patients with gastric adenoma, two biopsies from the antrum and corpus (patients with early gastric cancer, at least 5 cm distant from the tumour) were also required. Matching was effected blind to the results of the histopathological examinations with the exception of *H. pylori* status.

Paraffin wax embedded samples were sectioned and stained with haematoxylin and eosin and the Warthin-Starry stain for the detection of *H. pylori*. All histological data were evaluated by a single experienced pathologist (MS). Gastritis was evaluated in accordance with the updated Sydney system,¹ with the exception of intestinal metaplasia in the antrum or corpus, which was simply noted as present or absent, but not further subclassified.

For statistical analysis, analysis of variance (ANOVA) was used to compare age in the three groups. Features of gastritis (degree and activity of gastritis, presence of intestinal metaplasia) were compared using the χ^2 test or Fisher's exact test. A p value of less than 0.05 was considered significant.

RESULTS

Of the 118 patients with gastric adenoma, 60 patients (50.9%) were infected with *H. pylori*. In the remaining 58 patients,

autoimmune gastritis in the corpus was the predominant pattern, characterised by complete atrophic gastritis in 48 patients (40.7%) and partial atrophy with active destruction of the corpus glands and hyperplasia of parietal cells in two patients (1.7%). Eight patients (6.8%) had gastritis with typical features of an earlier *H. pylori* infection; that is, the presence of lymphoid aggregates, moderate lymphocytic infiltrate, but no detectable organisms (fig 2).

No differences were seen between the mean ages of the three matched groups with *H. pylori* infection and either gastric adenoma, early gastric cancer, or *H. pylori* gastritis alone (adenoma, 69.5 years; cancer, 68.6 years; gastritis, 69.6 years; all $p > 0.5$). However, there were highly significant differences in terms of the grade and activity of *H. pylori* gastritis in the antrum or corpus in patients with *H. pylori* gastritis alone in comparison with the other two groups. In these last two groups, gastritis in the antrum and corpus was more severe than in patients with gastritis alone (median grade and activity 2 v 1; tables 1 and 2). In addition, intestinal metaplasia in the antrum or corpus was more frequently present in the two groups with gastric tumours than in the group with gastritis only. The presence of intestinal metaplasia in the antrum was most prominent in the group with gastric cancer, whereas in the corpus this feature was more often present in patients with gastric adenoma. However, these differences between the two groups were not significant (tables 1 and 2).

DISCUSSION

Our data show that the proportion of patients with gastric adenoma and *H. pylori* infection is lower than that reported for patients with early gastric cancer. Only 50.9% of the patients with gastric adenoma were infected with the organisms, whereas our own previously published data, in addition to data from others, show incidence rates of *H. pylori* infection of around 80–90% for those with early gastric cancer.^{8–11} However, when *H. pylori* was detected, gastritis parameters were similar in patients with gastric adenoma and early gastric intestinal cancer. In both groups, *H. pylori* gastritis was comparatively severe in the antrum and the corpus, and intestinal metaplasia was a common finding.

In light of the fact that both *H. pylori* infection and gastric adenomas are thought to be premalignant lesions in a sequence leading to gastric cancer, why was *H. pylori* infection in the group of patients with gastric adenoma less frequent than expected? If there really is a sequence of *H. pylori* gastritis → metaplastic changes → adenoma → carcinoma, one would

Table 1 Differences in *Helicobacter pylori* gastritis in the antrum

	Gastric adenoma (n=60)	Early gastric cancer (n=60)	Only gastritis (n=60)
Degree of gastritis	2	2	1*
Activity of gastritis	2	2	1*
Intestinal metaplasia (%)	74.4	89.7	18.3*

Numbers are medians of gastritis score ranging from 0 to 3 (in accordance with the updated Sydney system) or percentage (intestinal metaplasia). *, $p < 0.001$ (χ^2 test). No significant differences were found between patients with gastric adenoma and those with early gastric cancer.

Table 2 Differences in *Helicobacter pylori* gastritis in the corpus

	Gastric adenoma (n=60)	Early gastric cancer (n=60)	Only gastritis (n=60)
Degree of gastritis	2	2	1*
Activity of gastritis	2	2	1*
Intestinal metaplasia (%)	41.9	24.1	6.7*

Numbers are medians of gastritis score ranging from 0 to 3 (in accordance with the updated Sydney system) or percentage (intestinal metaplasia). *, $p < 0.001$ (χ^2 test). No significant differences were found between patients with gastric adenoma and those with early gastric cancer.

Figure 3 Possible pathways leading from *Helicobacter pylori* gastritis to either gastric adenoma or gastric cancer.

expect to find at least as many *H pylori* infected patients with a “pre-malignant” adenoma as with gastric cancer.

However, in those patients with gastric adenoma but no concomitant *H pylori*, either body predominant atrophic gastritis (~43%) or gastritis showing the typical features of an earlier *H pylori* infection (~7%) was diagnosed. These data are in agreement with other reports showing a similarly high frequency of complete atrophy in the adenoma bearing stomach.^{12,13} Therefore, the incidence of complete atrophic gastritis in patients with gastric adenoma is much higher than in the general population¹⁴ or in populations with confirmed gastric cancer.⁸ We now know that in some cases infection with *H pylori* can induce severe inflammation with destruction of the corpus glands (“pre-atrophic stage”), which finally leads to complete atrophy of the corpus mucosa (“atrophic stage”).^{15,16} This stage of atrophy with loss of acid production does not favour the growth of *H pylori*.¹⁷ Thus, in some cases, *H pylori* may no longer be detectable, even though it initially induced the mucosal damage. Hence, we speculate that the high incidence of atrophic gastritis in the group of patients with gastric adenoma might reflect a “burned out” mucosa as a response to long lasting severe *H pylori* gastritis. In addition, the remaining 7% of patients with neither *H pylori* nor atrophic gastritis showed the typical features of gastritis often found after eradication of the organism.^{18,19}

However, when *H pylori* was present the gastritis resembled the gastric cancer phenotype of *H pylori* gastritis (that is, severe gastritis in the antrum and corpus, high percentage of intestinal metaplasia).^{20,21} Therefore, it could be speculated that this pattern of gastritis initially induced by *H pylori* causes both gastric adenoma and gastric cancer. However, the observation that many more patients develop cancer rather than adenoma,^{6,7} and that a comparatively high proportion of patients with gastric adenoma develop complete atrophy, whereas most patients with early gastric cancer still have active *H pylori* gastritis, remains to be clarified. A possible explanation could be that adenomas are relatively slow growing neoplasms so that the surrounding mucosa more often reaches an “end stage” of atrophic gastritis. In contrast, cancers progress more rapidly and fewer patients will reach complete atrophic gastritis before detection.

“The high incidence of atrophic gastritis in the group of patients with gastric adenoma might reflect a ‘burned out’ mucosa as a response to long lasting severe *H pylori* gastritis”

Of interest in this regard are data published by Hattori from Japan.²² On analysing gastric microcarcinomas of the intestinal type (diameters < 5 mm) he found no precursor lesions in the tumour margins, and concluded that intestinal metaplasia, dysplasia, and carcinoma arise coincidentally. This implies that no precursor is present for either of them, which is in direct contradiction to the Correa model postulating a cascade ending in gastric cancer. On the basis of Hattori’s data, it might be speculated that severe gastritis caused by *H pylori* infection

Take home messages

- Both gastric adenoma and gastric cancer of the intestinal type appear to arise in severely inflamed mucosa caused by *Helicobacter pylori* infection
- In contrast to early gastric cancers, gastric adenomas are more often found in association with complete atrophic gastritis in the body and are not necessarily premalignant lesions that will definitely lead to gastric cancer
- The different pathways that lead to either benign or malignant tumour growth need to be investigated further

leads to a constant cellular stress. As a result, the following mechanisms may be triggered: the cells of the mucosa undergo apoptosis leading to atrophy, or they become metaplastic (intestinal metaplasia), or—in the worst case—dysplastic. Hence, in contrast to colorectal cancer, we do not believe that there is a sequence of events beginning with gastritis leading to gastric adenoma and finally ending in gastric cancer of the intestinal type. In our opinion, mucosal stress is reflected by epithelial alterations such as metaplasia and/or atrophy, which may therefore be regarded as markers for an increased risk of gastric cancer. This does not mean that malignant growth derives from metaplasia/atrophy, making the latter a condition for the development of the former. The reason why far more cancers develop in active severe *H pylori* gastritis and not in complete atrophic gastritis, which, in contrast, is found disproportionately more often in association with gastric adenomas, might be the fact that active inflammation leads to a series of changes that are probably involved in carcinogenesis: the ammonia produced by *H pylori*,²³ increased cell proliferation,^{24,25} increased production of free oxygen radicals,²⁶ and the increased production of nitric oxide²⁷ may all trigger mutations in the stem cells. The development of intestinal metaplasia and/or atrophy might therefore be a physiological reaction of the gastric mucosa aimed at protecting itself from the constant stress caused by *H pylori*. If this theory were correct, one would expect adenomas with active *H pylori* associated gastritis in the surrounding mucosa to show an average higher grade of dysplasia. However, in our study only low grade dysplasia was found in adenomas, perhaps because most of the adenomas under investigation were not removed in total to check for areas with high grade dysplasia. It would be interesting to investigate whether adenomas with higher grades of dysplasia are indeed associated to a greater extent with active gastritis, similar to that found in early gastric cancers.

Authors’ affiliations

A Meining, Medical Department, University of Munich, 0-80336 Munich, Germany

B Riedl, Department of Pathology, Klinikum Bayreuth, D-95445 Bayreuth, Germany

M Stolte, Department of Pathology, Klinikum Bayreuth

Correspondence to: Professor M Stolte, Institut für Pathologie, Klinikum Bayreuth, Preuschwitzer Straße 101, D-95445 Bayreuth, Germany; Pathologie.Klinikum-Bayreuth@t-online.de

Accepted for publication 14 April 2002

REFERENCES

- 1 Dixon MF, Genta RM, Yardley JH, *et al*. Classification and grading of gastritis: the updated Sydney system. *Am J Surg Pathol* 1996;**20**:1161–81.
- 2 Correa P. A human model of gastric carcinogenesis. *Cancer Res* 1988;**48**:3554–60.
- 3 Tannapfel A. Molecular pathology of gastric carcinoma: current state of research. *Pathologie* 2001;**22**:37–43.

- 4 **Morson BC**, Sobin LH, Grundmann E, *et al*. Precancerous conditions and epithelial dysplasia in the stomach. *J Clin Pathol* 1980;**33**:711–21.
- 5 **Vogelstein B**, Fearon EF, Hamilton SR, *et al*. Genetic alterations during colorectal-tumor development. *N Engl J Med* 1988;**319**:525–32.
- 6 **Kamiya T**. Longterm follow-up study on gastric adenoma and its relation to gastric protruded carcinoma. *Cancer* 1982;**50**:2496–503.
- 7 **Berg JW**. Histological aspects of the relation between gastric adenomatous polyps and gastric cancer. *Cancer* 1958;**6**:1149–56.
- 8 **Miehlke S**, Hackelsberger A, Meining A, *et al*. Histological diagnosis of *Helicobacter pylori* gastritis is predictive of a high risk of gastric carcinoma. *Int J Cancer* 1997;**73**:837–9.
- 9 **Fiocca R**, Luinetti O, Villani L, *et al*. High incidence of *Helicobacter pylori* colonization in early gastric cancer and the possible relationship to carcinogenesis. *Eur J Gastroenterol Hepatol* 1993;**5**:2–8.
- 10 **Kikuchi S**, Wada O, Nakajima T, *et al*. Serum anti-*Helicobacter pylori* antibody and gastric carcinoma among young adults. *Cancer* 1995;**75**:2789–93.
- 11 **Tatsuta M**, Iishi H, Okuda S, *et al*. The association of *Helicobacter pylori* with differentiated-type early gastric cancer. *Cancer* 1993;**72**:1841–5.
- 12 **Komoto K**, Haruma K, Kamada T, *et al*. *Helicobacter pylori* infection and gastric neoplasia: correlations with histological gastritis and tumor histology. *Am J Gastroenterol* 1998;**93**:1271–6.
- 13 **Nakano H**, Persson B, Slezak P. Study of the gastric mucosal background in patients with gastric polyps. *Gastrointest Endosc* 1990;**36**:39–41.
- 14 **Strickland RG**, Mackay IR. A reappraisal of the nature and significance of chronic atrophic gastritis. *Dig Dis* 1973;**18**:426–40.
- 15 **Faller G**, Steininger H, Eck M, *et al*. Antigastric autoantibodies in *Helicobacter pylori* gastritis: prevalence, in-situ binding sites and clues for clinical relevance. *Virchows Arch* 1996;**427**:483–6.
- 16 **Negrini R**, Savio A, Poiesi C, *et al*. Antigenic mimicry between *Helicobacter pylori* and gastric mucosa in the pathogenesis of body atrophic gastritis. *Gastroenterology* 1996;**111**:655–65.
- 17 **Sipponen P**, Kekki M, Seppälä K, *et al*. The relationship between chronic gastritis and gastric acid secretion. *Aliment Pharmacol Ther* 1996;**10**:103–18.
- 18 **Valle J**, Seppälä K, Sipponen P, *et al*. Disappearance of gastritis after eradication of *Helicobacter pylori*. A morphometric study. *Scand J Gastroenterol* 1991;**26**:1057–65.
- 19 **Sipponen P**, Stolte M. Clinical impacts of routine antral and corpus biopsies. *Endoscopy* 1997;**29**:671–8.
- 20 **Meining A**, Bayerdörffer E, Müller P, *et al*. Gastric carcinoma risk index in patients infected with *Helicobacter pylori*. *Virchows Arch* 1998;**432**:311–14.
- 21 **Stolte M**, Eidt S. Lymphoid follicles in antral mucosa: immune response to *Campylobacter pylori*? *J Clin Pathol* 1989;**42**:1269–71.
- 22 **Hattori T**. Development of adenocarcinomas in the stomach. *Cancer* 1996;**57**:1528–34.
- 23 **Tsuji M**, Kawano S, Tsuji S, *et al*. Ammonia: a possible promoter in *Helicobacter pylori*-related gastric carcinogenesis. *Cancer Lett* 1992;**65**:15–18.
- 24 **Cahill RJ**, Sant S, Beattie S, *et al*. *Helicobacter pylori* and increased epithelial cell proliferation: a risk factor for cancer. *Eur J Gastroenterol Hepatol* 1994;**6**:1123–7.
- 25 **Bechi P**, Balzi M, Becciolini A, *et al*. *Helicobacter pylori* and cell proliferation of the gastric mucosa: possible implications for gastric carcinogenesis. *Am J Gastroenterol* 1996;**91**:271–6.
- 26 **Davies GR**, Simmonds NJ, Stevens TRJ, *et al*. *Helicobacter pylori* stimulates antral mucosal reactive oxygen metabolite production in vivo. *Gut* 1994;**35**:179–85.
- 27 **Wilson KT**, Ramanujam KS, Mobley HL, *et al*. *Helicobacter pylori* stimulates inducible nitric oxide synthase expression and activity in a murine macrophage cell line. *Gastroenterology* 1996;**111**:1524–33.

Want full text but don't have
a subscription?

Pay per view

For just \$8 you can purchase the full text of individual articles using our secure online ordering service. You will have access to the full text of the relevant article for 48 hours during which time you may download and print the pdf file for personal use.

www.jclinpath.com